Yale Nears Deal to Sell $2.5 Billion of Private Equity Stakes
The Ivy League school's endowment is in advanced talks on the portfolio sale, code-named 'Project Gatsby,' with an overall discount expected to be less than 10%, according to people with knowledge of the discussions, who asked not to be identified because the information is private. Potential buyers had valued parts of the portfolio at a haircut of as much as 15%, some of the people said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site
The multi-million-dollar investment provides NewAmsterdam Pharma with commercial capacity for fixed dose combination (FDC) of obicetrapib and ezetimibe to meet potentially high commercial demand. Piramal Pharma Solutions harnessed the strength of two additional facilities to efficiently produce the FDC, demonstrating the advantages of its integrated approach to development. MUMBAI, India, Aug. 21, 2025 /CNW/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), and NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) today announced the opening of a dedicated oral solid dosage (OSD) form suite at Piramal's facility in Sellersville, Pennsylvania, USA. As one of Piramal Pharma Solutions' focused drug product facilities, the Sellersville site provides comprehensive development and manufacturing services for various formulations, including several forms of OSDs. This addition will increase operational efficiency, helping NewAmsterdam Pharma to deliver its investigational drug therapy, if approved, to patients in need. The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities. This includes a reconfiguration of existing space to create a dedicated OSD suite that will be used exclusively for fixed dose combination products. The new suite is designed for turnkey, multi-layer tablet production, equipped with advanced capabilities and technology to support granulation, compression, tableting, and coating. This suite will facilitate the production of NewAmsterdam Pharma's investigational FDC, a non-statin cholesterol medication to reduce LDL-C. Although the suite is essential to the FDC's production, the partnership between Piramal Pharma Solutions and NewAmsterdam Pharma extends beyond the Sellersville site. Piramal's Ahmedabad PPDS, India site played a crucial role in the product's development, while its Pithampur, India site provides dual sourcing support. "We are thrilled to expand our OSD production capabilities at the Sellersville facility with this new manufacturing suite," said Peter DeYoung, CEO, Piramal Global Pharma. "This addition will not only enhance our production capacity and speed, but reinforce our commitment to patient centricity, too." "By investing in Piramal Pharma Solutions' Sellersville facility, we are enabling the manufacture of FDC with exceptional precision and efficiency to meet the future commercial demand," said Douglas Kling, COO, NewAmsterdam Pharma. "We are excited to continue growing alongside our trusted partner, Piramal Pharma Solutions, and thrilled about the potential for our collaboration to benefit countless patients around the globe." Patients aren't the only beneficiaries of this investment. Over the next five years, the suite is expected to create more than 20 new jobs at the Sellersville site, further contributing to the local economy and workforce. This investment underscores the commitment to continuous improvement shared by Piramal Pharma Solutions and NewAmsterdam Pharma. By adding the new production suite, both companies can operate with greater efficiency and capacity, ultimately bringing the FDC product, if approved, to more patients in need. About Obicetrapib Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage clinical biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. The Company seeks to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. About Piramal Pharma Solutions Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited. For more information visit: Piramal Pharma Solutions | LinkedIn| Facebook | X About Piramal Pharma Limited Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments. For more information, visit: Piramal Pharma | LinkedIn * Includes one facility via PPL's minority investment in Yapan Bio. Photo : : : : : View original content to download multimedia: SOURCE Piramal Pharma Solutions View original content to download multimedia:
Business Insider
8 minutes ago
- Business Insider
Centerbridge's cofounder says Wall Street is missing great hires
Wall Street's best hires don't look anything like the résumés it worships, said Jeff Aronson, a cofounder of Centerbridge Partners, a private equity firm managing more than $42 billion in assets. "I joke with people I couldn't get a job at my own firm," Aronson said in the Goldman Sachs "Exchanges" podcast on July 16. "I didn't go to an Ivy League school. I didn't graduate Phi Beta Kappa. I don't speak six languages. I didn't discover the cure for cancer when I was nine years old," he said in the recording uploaded on Tuesday. Aronson came up through Johns Hopkins, where he earned a BA with honors, and NYU School of Law, a path outside the Ivy League track that dominates Wall Street recruiting. US News and World Report ranks Baltimore-based Johns Hopkins sixth on its top national universities list. Wall Street is often stereotyped as an Ivy League stronghold. But data from Revelio Labs showed that only 11.7% of New York-based front-office workers at top firms — including JPMorgan Chase, Goldman Sachs, Morgan Stanley, and Citigroup — graduated from Ivy-plus schools, defined as the Ivy League plus Chicago, Stanford, Duke, and MIT. For Aronson, credentials aren't what make someone a great investor. What matters is mindset, he said. "Attributes, it's the same thing that you folks look for: people who are smart and hardworking and driven," he said. But he also prizes people who are "really intellectually curious." That's partly why he believes Wall Street keeps overlooking promising talent. "So we're all scrambling and tripping over ourselves, looking for the same people," Aronson said. But the real edge comes from hiring those who think independently, he said. He recalled asking candidates whether they compared notes with friends on the buy side — a question he phrased to encourage a "yes." But what he actually wanted to hear was a "no" — because he wanted people who would do their own work, and make their own decisions. That contrarian streak has also shaped where he looks for talent. Rather than only competing for the same Ivy League graduates as every other firm, Aronson also turned his attention to the City University of New York. With over 240,000 degree-program students, CUNY is the largest public urban university in the US, but one that few Wall Street recruiters seriously consider. "I met some of these kids, and they were smart and they were hardworking. But you know what else they had? They had grit. There was no millennial stuff," he said. "Zero. They had grit. Most of them worked their way through school. And so we started hiring them. And all they wanted — it reminded me a little like when I started. 'I just want a chance. Give me a chance,'" Aronson said. "And we started hiring these kids, and they were great," he said. Calling CUNY "the undiscovered jewel that no one's thinking about," Aronson has partnered with John Waldron, president of Goldman, and billionaire Mike Bloomberg to invest millions into programs linking its students with finance jobs. The initiative, he added, has been a win for everyone involved: "It's been a huge win for these students. It's been great for New York City. And it's been smart business."
Yahoo
35 minutes ago
- Yahoo
OffSec and Deloitte Collaborate to Strengthen Asia's Cyber Defences Through Workforce Development
NEW YORK, Aug. 21, 2025 /PRNewswire/ -- OffSec Services Ltd ("OffSec"), a leading global provider of cybersecurity training and certifications, is pleased to announce a strategic collaboration with Deloitte. This partnership will deliver advanced, real-world cybersecurity training programs across Asia, directly addressing the rising cyber threats and the ongoing shortage of skilled cybersecurity professionals. The collaboration unites OffSec's reputation for developing cybersecurity professionals with a focus on technical skill and adversary mindset, with Deloitte's enterprise cybersecurity expertise and regional insights. Together, OffSec and Deloitte aim to provide a high-impact training experience that equips security practitioners, enterprise teams, and aspiring professionals with the offensive and defensive capabilities needed to tackle today's most urgent security challenges. "Cybersecurity today demands more than awareness and a modern tech stack — it requires hands-on capability, continuous upskilling, and readiness for real-world, real-time threats. Through this exciting strategic partnership, OffSec brings our industry-leading simulation and skills development, combined with Deloitte's deep client, industry, and regulatory insight. Together, we're enabling more effective large-scale cyber transformations by building resilient, enterprise-grade security teams prepared to meet the evolving threat landscape." said Matt Collins, VP of APAC, OffSec. The training programmes will cover a wide range of advanced topics, including penetration testing, ethical hacking, exploit development, application and infrastructure security, and incident response. Courses will be delivered by certified instructors and conducted through OffSec's proven hands-on lab environments, while also incorporating Deloitte's business-contextualised scenarios and case studies. This ensures that participants not only gain technical proficiency but are also able to apply that knowledge in real-world operational settings. For organisations facing growing regulatory scrutiny and increasingly sophisticated attacks, the collaboration offers a scalable solution to upskilling their cybersecurity teams with globally respected certifications and battle-tested techniques. The initial rollout will begin in Singapore, with future expansion planned across key Asia Pacific markets. "As the threat environment is becoming increasingly complex and the talent gap is growing wider, this collaboration with OffSec addresses both challenges by providing practical, career-relevant training that builds technical depth while helping organisations establish a culture of security that is grounded in operational capability," said Lim Kim Hwee, Executive Director, Deloitte Learning Solutions. OffSec and Deloitte's shared mission through this collaborative effort is to elevate the cybersecurity profession across the region by making expert-level training more accessible, relevant, and aligned with the evolving needs of enterprises and regulators. With this collaboration, the two organisations are setting a new standard for how cybersecurity talent development should be approached: technically rigorous, business-aware, and regionally informed. About OffSec Services LtdOffSec is the leading provider of continuous professional and workforce development, training, and education for cybersecurity practitioners. OffSec's distinct pedagogy and practical, hands-on learning help organizations fill the infosec talent gap by training their teams on today's most critical skills. With the OffSec Learning Library featuring 7,000 hours of content, including over 1,800 videos, and 4,200+ labs. OffSec demonstrates its commitment to empowering individuals and organizations to fight cyber threats with indispensable cybersecurity skills and resources. OffSec also funds and maintains Kali Linux, the leading operating system for penetration testing, ethical hacking, and network security assessments. For more information, visit and follow us on X and LinkedIn. For media inquiries, please contact:Contact Person: Damian GohEmail: | View original content: SOURCE OffSec Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
